Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy

• Published in: Theranostics Vol. 13; no. 15; pp. 5546 - 5560
• Main Authors: Sun, Yujie, Guo, Yanxia, Liu, Xiaoqing, Liu, Jinling, Sun, Honglai, Li, Zhongying, Wen, Min, Jiang, Sheng-Nan, Tan, Wenzhi, Zheng, Jin Hai
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher 01.01.2023
• Subjects: Animals; Immunotherapy; Mice; Neoplasms - therapy; Research Paper; Salmonella typhimurium - genetics; Tumor Microenvironment; systemic safety; clinical translation; Salmonella typhimurium; VNP20009; bacterial-mediated cancer therapy
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.87340

Attenuated VNP20009 has been used to treat tumor-bearing mice and entered phase I clinical trials. However, its mild anticancer effect in clinical trials may be related to insufficient bacterial colonization and notable adverse effects with increasing dosages. Guanosine 5'-diphosphate-3'-diphosphate (ppGpp) synthesis-deficient is an attenuated strain with good biosafety and anticancer efficacy that has been widely investigated in various solid cancers in preclinical studies. Integration of the advantages of these two strains may provide a new solution for oncolytic bacterial therapy. We incorporated the features of ΔppGpp into VNP20009 and obtained the HCS1 strain by deleting and , and then assessed its cytotoxicity and antitumor activities . experiments revealed that the invasiveness and cytotoxicity of HCS1 to cancer cells were significantly lower than those of the VNP20009. Additionally, tumor-bearing mice showed robust cancer suppression when treated with different doses of HCS1 intravenously, and the survival time and cured mice were dramatically increased. Furthermore, HCS1 can increase the levels of pro-inflammatory cytokines in tumor tissues and relieve the immunosuppression in the tumor microenvironments. It can also recruit abundant immune cells into tumor tissues, thereby increasing immune activation responses. The newly engineered HCS1 strain manifests high prospects for cancer therapeutics and is a promising option for future clinical cancer immunotherapy.